Frontiers in Immunology · Nov 16, 2026

Longitudinal multimodal profiling characterizes shared and age-associated immune dynamics following recombinant zoster vaccination

By Xinyu Jiang, Pengfei Jin, Guolei Jiang et al.

Ageing-related immune remodelling may alter vaccine responsiveness, but how the two-dose recombinant zoster vaccine (RZV) engages cellular and systemic immune responses across older-adult age groups remains incompletely understood. We collected samples from adults aged 50–69 years and ≥70 years before each RZV dose, 1 day after each dose, and 30 days after the second dose. Clinical immunogenicity was assessed in 94 participants, with serum Olink proteomics available for 50 participants and single-cell RNA sequencing of peripheral blood mononuclear cells available for a nested subset of 18 participants. Across 440,042 high-quality immune cells assigned to 26 cell types, the 24-h response after dose 1 featured prominent classical-monocyte remodelling and a broadly induced interferon-associated programme across immune-cell compartments. The immediate responses to the two doses shared some cellular and serum-protein features but also differed between response windows. From 1 to 30 days after dose 2, transcriptional scores related to T-cell activation and effector and memory differentiation generally increased in several T-cell subsets. Activation-associated transcriptional scores also increased in naïve B cells. Selected cellular and serum-protein features differed between age groups. However, no statistically significant age-group differences were detected in the measured antigen-specific antibody or gE-specific CD4⁺ T-cell responses. By characterizing cellular and systemic immune changes across priming and boosting, this study provides a basis for future investigation of how RZV-associated immune trajectories relate to maintained immunogenicity in older adults.

The paperJournal siteInterventions

AgingResearch.News